|
Post by seanismorris on Apr 26, 2014 1:51:36 GMT -5
www.glassdoor.com/Reviews/MannKind-Reviews-E35192.htmIf anyone had asked, I would have said that Mannkinds strength was it's management team. Ex Employees at Mannkind seem to disagree... Many of the employees complaints about management can be tied to being laid off as a result of managements failure to convince the FDA to approve Afrezza. I'm sure many long term investors also share employees frustrations. But, hopefully not for much longer. Managements failure to communicate with the employes on the floor I'm sure is a common complaint for any company. One encouraging theme is ex employees are enthused about Afrezza and it's potential. And, many (I suspect) would like to get rehired by Mannkind once the stress at Mannkind (related to approval) is behind them and financial issues are alleviated.
I do wonder about about Alfred's role at Mannkind after Afrezza is approved. At 88 his role at Mannkind is probably closer to that of Chairman of the Board rather than CEO. Mr. Mann has many projects outside of Mannkind, and I'd expect his active participation at Mannkind will continue to decrease over the next year or two.
Opinions on the CEO succession at Mannkind:
www.mannkindcorp.com/about-us-executive-management-matthew.htm
Hakan S. Edstrom looks like strong successor to Mr. Mann as CEO. I'd prefer him over Matthew J. Pfeffer the current CFO. Mr. Pfeffer does seem to be the more public Executive figure at Mannkind showing up in this interview with Mr. Mann.
m.youtube.com/watch?v=bG3SrdzXEEM
Has anyone met with either Edstrom or Pfeffer and would like to share their opinion?
|
|